SBIR Phase I:Commercial Scale-up of Algal Fermentation Processes to Manufacture Eicosapentaenoic Acid

Award Information
Agency:
National Science Foundation
Branch
n/a
Amount:
$150,000.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1013471
Award Id:
99022
Agency Tracking Number:
1013471
Solicitation Year:
n/a
Solicitation Topic Code:
BT2
Solicitation Number:
n/a
Small Business Information
6610 Hidden Woods Trail, Cleveland, OH, 44143
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
832412592
Principal Investigator:
Charles Roe
PhD
(440) 684-0980
charles@algisys.com
Business Contact:
Charles Roe
PhD
(440) 684-0980
charles@algisys.com
Research Institution:
n/a
Abstract
This Small Business Innovation Research (SBIR) Phase I project is focused on completing the research necessary to begin commercializing the production of eicosapentaenoic acid (EPA) from algae. Algisys, LLC has partnered with Virginia Tech to further develop patent-pending technology for the production of EPA via algal fermentation, using inexpensive biodiesel-derived crude glycerol as a feedstock. This SBIR project is expected to result in the technical data necessary to initiate scale-up work on a process to convert waste glycerol into a high value nutritional oil containing EPA. Algisys plans to be the first company in the world to commercially produce EPA directly from algae. The broader/commercial impacts of this research involve the creation of a completely new source of EPA, which is currently derived solely from the oil of select types of marine fish. Fish oil contains low levels of omega-3 fatty acids, such as EPA, due to the consumption of algae by fish as part of the marine food chain. Omega-3s represent a multi-billion dollar market and are essential in the human diet for proper growth, development, and good health. Over 8,000 scientific studies and 40 years of research have shown that omega-3s have significant health benefits, and can be used to prevent/treat a variety of disorders: cardiovascular diseases, arthritis/inflammatory diseases, immune system disorders, Alzheimer?s, and macular degeneration. Algisys intends to help meet the rapidly growing demand for EPA using patent-pending technology that merits further development, and is believed to be both scalable and cost effective.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government